

Methods Patients diagnosed with vulvar SCC or VC between the years of 2004 and 2016 were identified in the NCDB. OS was assessed with Kaplan-Meier curves and the log-rank test. Construction of a Cox model compared survival after controlling for confounding variables.

Results The reported incidence of SCC of the vulva has significantly increased since 2004 ($p < 0.0001$). In contrast, the incidence of VC has remained stable since 2004 ($p = 0.344$). Compared to SCC, VC was significantly more likely to be diagnosed in older women ($p < 0.0001$) and treated with surgery alone ($p < 0.0001$). However, on propensity score weighted analysis there was a trend toward improved OS in women with VC compared to those with SCC ($p = 0.0794$). Multivariable Cox survival analysis showed an improvement in OS in VC patients treated with both primary site and regional lymph node surgery compared to primary site surgery alone (HR 0.67, 95% confidence interval [CI] 0.46 – 0.97, $p = 0.0357$).

Conclusions Verrucous carcinoma is more likely to present in women at an older age. Regional lymph node surgery in addition to primary site surgery significantly improves OS in VC patients.

EPV289/#657

EPIDEMIOLOGICAL PROFILE OF PATIENTS WITH MALIGNANT VULVA NEOPLASIA ATTENDED AT SANTA MARCELINA ITAQUERA HOSPITAL – SAO PAULO

¹JA Barbosa*, ²M Mesquita, ³S Sanches, ²C Sousa, ²M Silva, ²I Manchini, ²M Brandão, ²C Gomez, ²T Almeida. ¹Casa de Saúde Santa Marcelina, Gynecology Oncology, Sao Paulo, Brazil; ²Casa de Saúde Santa Marcelina, Gynecologic Oncology, Sao Paulo, Brazil

10.1136/ijgc-2021-IGCS.360

Objectives Objective: To study the epidemiological profile of patients diagnosed with vulvar malignancy seen at Santa Marcelina Itaquera Hospital (HSM) in São Paulo.

Methods Analysis of medical records of patients undergoing follow-up at the Gynecology Oncology outpatient clinic between the years 2008 to 2020. The information analyzed were: age, parity, smoking, histological type of the tumor, neoadjuvance, surgical treatment, adjuvance, recurrence, lymph node involvement and death.

Results

Result 45 patients were seen, whose average age was 66 years, which numerically represents 51.11% of the patients seen; 26.66% were smokers and the most common histological type is squamous cell carcinoma, marking 82.22% of all other types identified. Five patients (11.11%) were classified as stage I, fifteen (33.33%) stage II, thirteen (28.88%) stage III and twelve (26.66) of stage IV patients. Within this scenario, neoadjuvant therapy was part of 60% of the cases; surgical treatment 80% and adjuvance 62.22%. Sixty-four percent of the patients did not experience recurrence or disease progression. Forty percent of patients who did surgical procedure with lymphadenectomy had lymph node involvement and twenty-four patients (53.33%) died.

Conclusions

Conclusion The epidemiological profile of patients are consistent with the literature, from the age group, histological type, percentage of death and recurrence. The high rate of death is mainly related to late diagnosis, although neoadjuvant treatment allows surgery in advanced cases.

EPV290/#90

LONG-TERM RESULTS OF PRIMARY VAGINAL CANCER TREATMENT: THE BELARUS NATIONAL CANCER CENTRE EXPERIENCE

¹O Matylevich*, ²H Trukhan, ¹E Dolomanova, ¹D Rouski, ³O Zubets, ¹S Mavrichiev. ¹NN Alexandrov National Cancer Centre of Belarus, Gynecologic Oncology Department, Minsk, Belarus; ²Belarusian Medical Academy of Postgraduate Education, Department of Oncology, Minsk, Belarus; ³NN Alexandrov National Cancer Centre of Belarus, Cancer Control Department, Minsk, Belarus

10.1136/ijgc-2021-IGCS.361

Objectives To study the long-term results of treatment of vaginal cancer (VC) patients and to evaluate the results of diagnosis and treatment of patients living in urban and rural areas.

Methods The data of 70 patients with primary VC treated at NN Alexandrov National Cancer Centre of Belarus from 2000 to 2019 were included. The median age was 64 years (range, 32–87). Morphology in 91.5% (64/70) cases was squamous cell cancer, in 7.1% (5/70) – adenocarcinoma, in 1.4% (1/70) – adenosquamous carcinoma. The distribution by the stage was as follows: Stage I in 17 (24.3%) patients, Stage II in 30 (42.9%), Stage III in 12 (17.1%), Stage IV in 11 (15.7%) cases. Treatment was performed in 82.8% (58/70) cases: in 94.1% (16/17) for Stage I disease, in 83.3% (25/30) for Stage II, in 91.7% (11/12) for Stage III, and in 54.5% (6/11) for Stage IV.

Results The median follow-up time was 33 months (range, 1–220). A total of 42 women died: 28 from progression of VC and 14 from other diseases. Overall survival (OS) was 31.9 ± 6.8%, median survival - 41 months (95% CI 0.0–105.3). Disease-specific survival (DSS) for the entire group was 54.5 ± 6.8%, median not reached. The overall survival rate of urban women was 44.8 ± 10.6%, rural - 22.5 ± 8.2%, $p = 0.142$; DSS - 57.6 ± 10.5% and 53.0 ± 8.4%, $p = 0.448$, respectively.

Conclusions The DSS rate was 54.0 ± 6.8%; the OS rate did not exceed 31.9 ± 6.8%. Rural residence was not associated with late stage at diagnosis or receipt of treatment.

EPV293/#425

EFFECT ON OVERALL SURVIVAL OF CANCER PROGRAM-LEVEL VARIATION IN THE USE OF NEOADJUVANT CHEMOTHERAPY FOR ADVANCED OVARIAN CANCER: A DIFFERENCE-IN-DIFFERENCES STUDY

¹A Melamed*, ²JA Rauh-Hain, ¹A Gockley, ²R Nitecki, ³P Ramirez, ⁴D Hershman, ⁵N Keating, ¹J Wright. ¹Columbia University College of Physicians and Surgeons, Gynecologic Oncology, New York City, USA; ²University of Texas MD Anderson Cancer Center, Gynecologic Oncology, Houston, USA; ³University of Texas MD Anderson Cancer Center, Gynecologic Oncology and Reproductive Medicine, Houston, USA; ⁴Herbert Irving Comprehensive Cancer Center, Oncology, New York City, USA; ⁵Harvard Medical School, Health Policy, Boston, USA

10.1136/ijgc-2021-IGCS.362

Objectives To evaluate the effect of cancer program-level variations in use of neoadjuvant chemotherapy (NACT) on overall survival among patients with advanced ovarian cancer.

Methods We included women with advanced-stage epithelial ovarian cancer treated 2004–2015 in Commission on Cancer-accredited cancer programs that began administering NACT liberally or continued to restrict its use after the publication of a randomized trial in 2010. We used flexible parametric survival models to perform a difference-in-differences analysis